Mohammed A. Dahab

1.3k total citations · 1 hit paper
37 papers, 1.1k citations indexed

About

Mohammed A. Dahab is a scholar working on Organic Chemistry, Molecular Biology and Oncology. According to data from OpenAlex, Mohammed A. Dahab has authored 37 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Organic Chemistry, 21 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in Mohammed A. Dahab's work include Synthesis and biological activity (17 papers), Angiogenesis and VEGF in Cancer (14 papers) and Bioactive Compounds and Antitumor Agents (8 papers). Mohammed A. Dahab is often cited by papers focused on Synthesis and biological activity (17 papers), Angiogenesis and VEGF in Cancer (14 papers) and Bioactive Compounds and Antitumor Agents (8 papers). Mohammed A. Dahab collaborates with scholars based in Egypt, Saudi Arabia and Indonesia. Mohammed A. Dahab's co-authors include Ibrahim H. Eissa, Eslam B. Elkaeed, Ahmed M. Metwaly, Hazem A. Mahdy, Hazem Elkady, Nawaf A. Alsaif, Ahmed A. Al‐Karmalawy, Ahmad J. Obaidullah, Mohammed M. Alanazi and Mohammed S. Taghour and has published in prestigious journals such as The Journal of Organic Chemistry, Molecules and RSC Advances.

In The Last Decade

Mohammed A. Dahab

35 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular Docking and Dynamics Simulation Revealed the Potential Inhibitory Activity of ACEIs Against SARS-CoV-2 Targeting the hACE2 Receptor

2021 209 citations Ahmed A. Al‐Karmalawy, Mohammed A. Dahab et al. Frontiers in Chemistry profile →

Peers

Countries citing papers authored by Mohammed A. Dahab

Since Specialization

Citations

This map shows the geographic impact of Mohammed A. Dahab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammed A. Dahab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammed A. Dahab more than expected).

Fields of papers citing papers by Mohammed A. Dahab

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammed A. Dahab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammed A. Dahab. The network helps show where Mohammed A. Dahab may publish in the future.

Co-authorship network of co-authors of Mohammed A. Dahab

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammed A. Dahab. A scholar is included among the top collaborators of Mohammed A. Dahab based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammed A. Dahab. Mohammed A. Dahab is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Design, synthesis, anticancer evaluation, biological screening, and computational study of novel 6,7-dimethoxyquinazoline derivatives as VEGFR-2 inhibitors and apoptotic inducers 2025 ·European Journal of Medicinal Chemistry ·(unknown), Abdallah E. Abdallah, Mohammed A. Dahab, Abeer A. Mohamed, İsmail Çeli̇k, Wafa A. Bawazir, (unknown), (unknown), (unknown), Mohamed Ayman El‐Zahabi	0
2	New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies 2024 ·Biochimica et Biophysica Acta (BBA) - General Subjects ·Hazem Elkady, Hazem A. Mahdy, Mohammed S. Taghour, Mohammed A. Dahab, Alaa Elwan, Mohamed Hagras, (unknown), Ibrahim M. Ibrahim, Dalal Z. Husein, Eslam B. Elkaeed, Aisha A. Alsfouk, Ahmed M. Metwaly, Ibrahim H. Eissa	13
3	Exploration of the VEGFR-2 inhibition activity of phthalazine derivatives: design, synthesis, cytotoxicity, ADMET, molecular docking and dynamic simulation 2024 ·RSC Advances ·(unknown), (unknown), Mohammed A. Dahab, (unknown), Khaled El‐Adl	4
4	Phthalazine Derivatives as VEGFR‐2 Inhibitors: Docking, ADMET, Synthesis, Design, Anticancer Evaluations, and Apoptosis Inducers 2024 ·Drug Development Research ·(unknown), (unknown), Mohammed A. Dahab, (unknown), Khaled El‐Adl	0
5	Rationale, in silico docking, ADMET profile, design, synthesis and cytotoxicity evaluations of phthalazine derivatives as VEGFR-2 inhibitors and apoptosis inducers 2024 ·RSC Advances ·(unknown), (unknown), Mohammed A. Dahab, (unknown), Khaled El‐Adl	3
6	New Thieno[2,3-d]pyrimidines as Anticancer VEGFR-2 Inhibitors with Apoptosis Induction: Design, Synthesis, and Biological and In Silico Studies 2024 ·Medicinal Chemistry ·(unknown), (unknown), Mohammed A. Dahab, Eslam B. Elkaeed, Bshra A. Alsfouk, Ibrahim M. Ibrahim, Ahmed M. Metwaly, Ibrahim H. Eissa	2
7	New thiazolidine-2,4-diones as effective anti-proliferative and anti-VEGFR-2 agents: Design, synthesis, in vitro, docking, MD simulations, DFT, ADMET, and toxicity studies 2023 ·Computational Biology and Chemistry ·Hazem Elkady, (unknown), (unknown), Mohammed S. Taghour, Mohammed A. Dahab, Hazem A. Mahdy, Alaa Elwan, Hanan Al-Ghulikah, Eslam B. Elkaeed, Ibrahim M. Ibrahim, Dalal Z. Husein, Ahmed M. Metwaly, Ibrahim H. Eissa	16
8	Synthesis, biological evaluation and computer-aided discovery of new thiazolidine-2,4-dione derivatives as potential antitumor VEGFR-2 inhibitors 2023 ·RSC Advances ·Hazem Elkady, (unknown), Alaa Elwan, Mohammed S. Taghour, Hazem A. Mahdy, Mohammed A. Dahab, Eslam B. Elkaeed, Bshra A. Alsfouk, Ibrahim M. Ibrahim, Dalal Z. Husein, E. S. E. Hafez, Amira M.G. Darwish, Ahmed M. Metwaly, Ibrahim H. Eissa	16
9	New Theobromine Derivatives Inhibiting VEGFR-2: Design, Synthesis, Antiproliferative, Docking and Molecular Dynamics Simulations 2023 ·Future Medicinal Chemistry ·Hazem A. Mahdy, Hazem Elkady, Mohammed S. Taghour, Alaa Elwan, Mohammed A. Dahab, Mohamed A. Elkady, Elsayed G.E. Elsakka, Eslam B. Elkaeed, Bshra A. Alsfouk, Ibrahim M. Ibrahim, Ibrahim H. Eissa, Ahmed M. Metwaly	24
10	AN OVERVIEW OF QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS 2023 ·Al-Azhar Journal of Pharmaceutical Sciences ·(unknown), Abeer A. Mohamed, Mohammed A. Dahab, Mohamed Ayman El‐Zahabi	4
11	Design, synthesis, docking, MD simulations, and anti-proliferative evaluation of thieno[2,3- d ]pyrimidine derivatives as new EGFR inhibitors 2023 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·(unknown), Mohammed A. Dahab, Eslam B. Elkaeed, Aisha A. Alsfouk, Ibrahim M. Ibrahim, Ahmed M. Metwaly, Ibrahim H. Eissa	13
12	New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies 2022 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·Eslam B. Elkaeed, Mohammed S. Taghour, Hazem A. Mahdy, Wagdy M. Eldehna, Nehal M. El‐Deeb, Ahmed M. Kenawy, Bshra A. Alsfouk, Mohammed A. Dahab, Ahmed M. Metwaly, Ibrahim H. Eissa, Mohamed Ayman El‐Zahabi	58
13	Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation 2022 ·Molecules ·Alaa Elwan, Abdallah E. Abdallah, Hazem A. Mahdy, Mohammed A. Dahab, Mohammed S. Taghour, Eslam B. Elkaeed, Ahmed B. M. Mehany, (unknown), (unknown), Aisha A. Alsfouk, Hazem Elkady, Ibrahim H. Eissa	51
14	Design, synthesis, molecular modeling and biological evaluation of novel Benzoxazole-Benzamide conjugates via a 2-Thioacetamido linker as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers 2022 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·Ibrahim H. Eissa, Radwan El‐Haggar, Mohammed A. Dahab, Marwa F. Ahmed, Hazem A. Mahdy, Reem I. Alsantali, Alaa Elwan, Nicolas Masurier, Samar S. Fatahala	17
15	Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, in silico studies, and antiproliferative evaluation 2022 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·Mohammed S. Taghour, Hazem A. Mahdy, (unknown), (unknown), (unknown), Alaa Elwan, Mohammed A. Dahab, Eslam B. Elkaeed, Aisha A. Alsfouk, Mohamed M. Khalifa, Ibrahim H. Eissa, Hazem Elkady	43
16	Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies 2021 ·Bioorganic & Medicinal Chemistry ·Nawaf A. Alsaif, Mohammed S. Taghour, Mohammed M. Alanazi, Ahmad J. Obaidullah, Wael A. Alanazi, Abdullah F. Alasmari, (unknown), Mohammed A. Dahab, Hazem A. Mahdy	32
17	Molecular Docking and Dynamics Simulation Revealed the Potential Inhibitory Activity of ACEIs Against SARS-CoV-2 Targeting the hACE2 Receptor breakdown → 2021 ·Frontiers in Chemistry ·Ahmed A. Al‐Karmalawy, Mohammed A. Dahab, Ahmed M. Metwaly, Sameh S. Elhady, Eslam B. Elkaeed, Ibrahim H. Eissa, Khaled M. Darwish	209
18	New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies 2021 ·Journal of Enzyme Inhibition and Medicinal Chemistry ·Hazem Elkady, Alaa Elwan, Hesham A. El‐Mahdy, Ahmed S. Doghish, Ahmed Ismail, Mohammed S. Taghour, Eslam B. Elkaeed, Ibrahim H. Eissa, Mohammed A. Dahab, Hazem A. Mahdy, Mohamed M. Khalifa	112
19	New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis 2021 ·Bioorganic Chemistry ·Nawaf A. Alsaif, Mohammed A. Dahab, Mohammed M. Alanazi, Ahmad J. Obaidullah, Abdulrahman A. Almehizia, (unknown), (unknown), Hazem A. Mahdy, Hazem Elkady	95
20	Hordatines as a Potential Inhibitor of COVID-19 Main Protease and RNA Polymerase: An In-Silico Approach 2020 ·Natural Products and Bioprospecting ·Mohammed A. Dahab, Mostafa M. Hegazy, (unknown)	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact